Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research.
The collaboration leverages Tempus' AI-powered data analytics platform, Lens, to analyze and restructure the Center's repository of genomic data. Together, the Center and Tempus teams will work to uncover genomic patterns that have the potential to advance the understanding of Alzheimer's disease, investigate the gene and cell types affected, enable the development of new therapeutics, and accelerate the creation of novel clinical applications. By harnessing Lens' advanced AI capabilities, the collaboration aims to generate actionable insights that drive the discovery of targeted therapies and significantly improve patient outcomes.
'We are excited to collaborate with the Abrams Research Center on Neurogenomics to confront one of the most complex and pressing medical challenges of our time,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'By integrating our AI platform with the Center's pioneering work in neurogenomics, we are opening new avenues for discovery. Together, we strive to advance research for Alzheimer's and bring hope and tangible impact to patients and families affected by this devastating disease.'
'This collaboration with Tempus represents an important step forward in our mission to harness cutting-edge technologies to transform Alzheimer's research,' said David Gate, PhD, assistant professor in Ken and Ruth Davee Department of Neurology at Feinberg and head of The Abrams Research Center on Neurogenomics. 'We share a commitment to deepen our understanding of the genomic underpinnings of Alzheimer's disease and accelerate the development of more targeted, effective interventions.'
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding the expected outcomes and benefits of the collaboration with the Abrams Research Center on Neurogenomics to advance research for Alzheimer's disease are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
32 minutes ago
- Hamilton Spectator
Pope Leo XIV flags AI impact on kids' intellectual and spiritual development
ROME (AP) — Pope Leo XIV warned Friday that artificial intelligence could negatively impact the intellectual, neurological and spiritual development of young people as he pressed one of the priorities of his young pontificate. History's first American pope sent a message to a conference of AI and ethics, part of which was taking place in the Vatican in a sign of the Holy See's concern for the new technologies and what they mean for humanity. In the message, Leo said any further development of AI must be evaluated according to the 'superior ethical criterion' of the need to safeguard the dignity of each human being while respecting the diversity of the world's population. He warned specifically that new generations are most at risk given they have never had such quick access to information. 'All of us, I am sure, are concerned for children and young people, and the possible consequences of the use of AI on their intellectual and neurological development,' he said in the message. 'Society's well-being depends upon their being given the ability to develop their God-given gifts and capabilities,' and not allow them to confuse mere access to data with intelligence. 'In the end, authentic wisdom has more to do with recognizing the true meaning of life, than with the availability of data,' he said. Leo, who was elected in May after the death of Pope Francis, has identified AI as one of the most critical matters facing humanity, saying it poses challenges to defending human dignity, justice and labor. He has explained his concern for AI by invoking his namesake, Pope Leo XIII . That Leo was pope during the dawn of the Industrial Revolution and made the plight of workers, and the need to guarantee their rights and dignity, a key priority. Toward the end of his pontificate, Francis became increasingly vocal about the threats to humanity posed by AI and called for an international treaty to regulate it. Francis said politicians must take the lead in making sure AI remains human-centric, so that decisions about when to use weapons or even less-lethal tools always remain made by humans and not machines. ___ Associated Press religion coverage receives support through the AP's collaboration with The Conversation US, with funding from Lilly Endowment Inc. The AP is solely responsible for this content. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Yahoo
41 minutes ago
- Yahoo
BBC Threatens Injunction Against Perplexity AI
Perplexity is in hot water after the BBC accused the AI search startup of quietly scraping its entire archive to train its default model, warning that it'll head to court if those copies aren't deleted and a compensation plan isn't on the table. Warning! GuruFocus has detected 4 Warning Signs with NVDA. In a letter leaked to the Financial Times, the U.K. broadcaster gave Perplexity CEO Aravind Srinivas an ultimatum: stop hoovering up BBC content, erase whatever's already stored for AI training, and figure out how much you'll pay for infringing on our IP. Backed by Nvidia (NASDAQ:NVDA) and Amazon (NASDAQ:AMZN) Co-Founder Jeff BezosPerplexity didn't hold back in its response, branding the BBC's move manipulative and opportunistic and suggesting the broadcaster just doesn't get how web tech and copyright law actually work. This isn't their first brush with big publishersback in October, the New York Times sent a cease?and?desist over similar scraping claimsso it underscores a bigger headache for model builders: litigation risk is growing just as fast as the data they're hungry for. Some of the deep-pocketed players are sidestepping this by licensing content outright, but for cash-strapped startups, that could mean tighter margins and slower rollouts if court dates start piling up. This article first appeared on GuruFocus.
Yahoo
41 minutes ago
- Yahoo
With 59% institutional ownership, eHealth, Inc. (NASDAQ:EHTH) is a favorite amongst the big guns
Institutions' substantial holdings in eHealth implies that they have significant influence over the company's share price The top 17 shareholders own 51% of the company Insiders have been buying lately AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Every investor in eHealth, Inc. (NASDAQ:EHTH) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 59% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. In the chart below, we zoom in on the different ownership groups of eHealth. Check out our latest analysis for eHealth Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that eHealth does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of eHealth, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It looks like hedge funds own 14% of eHealth shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that 8 Knots Management, LLC is the largest shareholder with 8.1% of shares outstanding. For context, the second largest shareholder holds about 5.6% of the shares outstanding, followed by an ownership of 4.4% by the third-largest shareholder. In addition, we found that Francis Soistman, the CEO has 2.3% of the shares allocated to their name. After doing some more digging, we found that the top 17 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. We can report that insiders do own shares in eHealth, Inc.. As individuals, the insiders collectively own US$7.4m worth of the US$123m company. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying. With a 21% ownership, the general public, mostly comprising of individual investors, have some degree of sway over eHealth. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. It's always worth thinking about the different groups who own shares in a company. But to understand eHealth better, we need to consider many other factors. Take risks for example - eHealth has 2 warning signs we think you should be aware of. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
